<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29413/ABS.2025-10.6.9</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-5740</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ ЛАБОРАТОРНАЯ ДИАГНОСТИКА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL LABORATORY DIAGNOSIS</subject></subj-group></article-categories><title-group><article-title>Разработка спектрофотометрического метода определения фенотипа ацетилирования на основе метаболизма кофеина</article-title><trans-title-group xml:lang="en"><trans-title>A spectrophotometric method for determining the phenotype of acetylation based on caffeine metabolism</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5080-9225</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Родионова</surname><given-names>Л. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Rodionova</surname><given-names>L. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Родионова Любовь Викторовна – кандидат биологических наук, заведующий лабораторией клеточной патофизиологии и биохимии, ведущий научный сотрудник </p><p>664003, г. Иркутск, ул. Борцов Революции, 1</p></bio><bio xml:lang="en"><p>Lyubov V. Rodionova – Cand. Sc. (Biol.), Head of the Laboratory of Cell Pathophysiology and Biochemistry </p><p>Bortsov Revolyutsii str. 1, Irkutsk 664003</p></bio><email xlink:type="simple">greidmacho@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4032-8575</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Животенко</surname><given-names>А. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhivotenko</surname><given-names>A. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Животенко Александр Петрович – научный сотрудник НКО нейрохирургии </p><p>664003, г. Иркутск, ул. Борцов Революции, 1</p></bio><bio xml:lang="en"><p>Aleksandr P. Zhivotenko – Research Officer at the Clinical Research Department of Neurosurgery </p><p>Bortsov Revolyutsii str. 1, Irkutsk 664003</p></bio><email xlink:type="simple">sivotenko@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4482-6130</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Самойлова</surname><given-names>Л. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Samoilova</surname><given-names>L. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Самойлова Лилия Григорьевна – младший научный сотрудник лаборатории клеточной патофизиологии и биохимии </p><p>664003, г. Иркутск, ул. Борцов Революции, 1</p></bio><bio xml:lang="en"><p>Liliya G. Samoilova – Junior Research Officer at the Laboratory of Cell Pathophysiology and Biochemistry </p><p>Bortsov Revolyutsii str. 1, Irkutsk 664003</p></bio><email xlink:type="simple">popovalg@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9189-3323</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ларионов</surname><given-names>С. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Larionov</surname><given-names>S. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ларионов Сергей Николаевич – зав. НКО нейрохирургии</p><p>664003, г. Иркутск, ул. Борцов Революции, 1</p></bio><bio xml:lang="en"><p>Sergey N. Larionov – Dr. Sc. (Med.), Leading Research Officer at the Clinical Research Department of Neurosurgery</p><p>Bortsov Revolyutsii str. 1, Irkutsk 664003</p></bio><email xlink:type="simple">snlar@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное научное учреждение «Иркутский научный центр хирургии и травматологии»</institution></aff><aff xml:lang="en"><institution>Irkutsk Scientific Center of Surgery and Traumatology</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>14</day><month>01</month><year>2026</year></pub-date><volume>10</volume><issue>6</issue><fpage>76</fpage><lpage>92</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Родионова Л.В., Животенко А.П., Самойлова Л.Г., Ларионов С.Н., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Родионова Л.В., Животенко А.П., Самойлова Л.Г., Ларионов С.Н.</copyright-holder><copyright-holder xml:lang="en">Rodionova L.V., Zhivotenko A.P., Samoilova L.G., Larionov S.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/5740">https://www.actabiomedica.ru/jour/article/view/5740</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Многочисленность заболеваний и состояний, при которых ключевую роль имеет NAT2, диктует необходимость исследования как генотипа, так и фенотипа ацетилирования. Такие подходы позволят определять группы риска, а также подбирать эффективные дозы лекарств, предотвращая развитие побочных эффектов и определяя оптимальную терапевтическую дозу.</p></sec><sec><title>Цель</title><p>Цель. Разработать экономичный и простой метод определения фенотипа ацетилирования на основе спектрофотометрического определения скорости метаболизма кофеина в качестве тестового препарата.</p></sec><sec><title>Методы</title><p>Методы. Работа проведена в группе из 52 пациентов со стенозами позвоночного канала (средний возраст 51,04 ± 9,671 лет) и 32 условно здоровыми людьми (средний возраст 53,32 ± 0,933 лет). В образцах крови и мочи до и после приема кофеина определяли креатинин и мочевую кислоту, а также измеряли оптическую плотность мочи на 272 нм. Для оценки скорости ацетилирования предложен расчет интегрального прогностического показателя. В качестве референсного метода использовали ПЦР со специфическими праймерами для выявления полиморфизмов NAT2, отражающихся на скорости ацетилирования.</p></sec><sec><title>Результаты</title><p>Результаты. Разработан эффективный, легко выполнимый алгоритм, включающий технологию сбора, подготовки и анализа образцов крови и мочи до и после применения кофеина в качестве тестового препарата, расчет интегрального прогностического показателя для оценки скорости реакций ацетилирования. Метод пригоден для косвенной, более простой и мало затратной оценки скорости протекания реакций ацетилирования по сравнению с молекулярно-генетическими исследованиями.</p></sec><sec><title>Заключение</title><p>Заключение. Определение фенотипа ацетилирования с помощью предлагаемых аналитических процедур позволяет выявить индивидуальные различия в метаболизме соединительной ткани, искать подходы к прогнозированию исходов лечения в зависимости от полиморфного варианта NAT2 с выделением групп риска. Полученные данные можно использовать для поиска новых звеньев патогенеза, реализации механизмов боли и фиброзирования.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Justifiation</title><p>Justifiation. The multiplicity of diseases and conditions in which NAT2 plays a key role, dictates the need to study both the genotype and the phenotype of acetylation. Such approaches will make it possible to identify risk groups, as well as select effective doses of drugs, preventing the development of side effects and determining the optimal therapeutic dose.</p></sec><sec><title>Methods</title><p>Methods. The work was performed in a group of 52 patients with spinal canal stenosis (average age 51.04 ± 9.671 years) and 32 conditionally healthy people (average age 53.32 ± 0.933 years). Creatinine and uric acid were determined in blood and urine samples before and after taking caffeine, and the optical density of urine at 272 nm was measured. To estimate the acetylation rate, the calculation of an integral predictive indicator is proposed. PCR with specific primers was used as a reference method to detect NAT2 polymorphisms affecting the acetylation rate.</p></sec><sec><title>Results</title><p>Results. An effective, easily executable algorithm has been developed that includes the technology of collecting, preparing and analyzing blood and urine samples before and after using caffeine as a test drug, and calculating an integral predictive indicator to assess the rate of acetylation reactions. The method is suitable for indirect, simpler and less costly assessment of the rate of acetylation reactions compared with molecular genetic studies.</p></sec><sec><title>Conclusion</title><p>Conclusion. The determination of the acetylation phenotype using the proposed analytical procedures makes it possible to identify individual differences in connective tissue metabolism, and to seek approaches to predicting treatment outcomes depending on the polymorphic variant of NAT2 with the identification of risk groups. The data obtained can be used to search for new links in pathogenesis, to implement the mechanisms of pain and fibrosis.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ацетилтрансфераза NAT2</kwd><kwd>ацетилирование</kwd><kwd>прогнозирование</kwd><kwd>кофеин</kwd><kwd>мочевая кислота</kwd><kwd>креатинин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>acetyltransferase NAT2</kwd><kwd>acetylation</kwd><kwd>prediction</kwd><kwd>caffeine</kwd><kwd>uric acid</kwd><kwd>creatinine</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках бюджетной темы ФГБНУ «Иркутский научный центр хирургии и травматологии» «Совершенствование методов диагностики, профилактики и лечения дегенеративно-дистрофических заболеваний позвоночника и таза на основе управления патофизиологическими механизмами в формировании патологии».</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Walls KM, Joh JY, Martinez MM, Hong KU, Hein DW. Metabolic effects of heterocyclic amines on insulin-induced AKT phosphorylation and gluconeogenic gene expression are modified by N -acetyltransferase 2 genetic polymorphism. Pharmacogenet Genomics. 2025; 35(4): 119-126. doi: 10.1097/FPC.0000000000000559</mixed-citation><mixed-citation xml:lang="en">Walls KM, Joh JY, Martinez MM, Hong KU, Hein DW. Metabolic effects of heterocyclic amines on insulin-induced AKT phosphorylation and gluconeogenic gene expression are modified by N -acetyltransferase 2 genetic polymorphism. Pharmacogenet Genomics. 2025; 35(4): 119-126. doi: 10.1097/FPC.0000000000000559</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Тийс Р.П., Осипова Л.П., Галиева Э.Р., Личман Д.В., Воронина Е.Н., Мелихова А.В., и др. Полиморфизм вариантов гена N-ацетилтрансферазы 2 (NAT2) и анализ генной сети. Биомедицинская химия. 2021; 67(3), 213-221. doi: 10.18097/PBMC20216703213</mixed-citation><mixed-citation xml:lang="en">Tiis RP, Osipova LP, Galieva ER, Lichman DV, Voronina EN, Melikhova AV, et al. N-aсetyltransferase (NAT2) gene polymorphism and gene network analysis. Biomed Khim. 2021; 67(3): 213-221. (In Russ.). doi: 10.18097/PBMC20216703213</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Choudhury C, et al. The arylamine N-acetyltransferases as therapeutic targets in metabolic diseases associated with mitochondrial dysfunction. Pharmacological Reviews. 2024; 76(2): 300-320. doi: 10.1124/pharmrev.123.000835</mixed-citation><mixed-citation xml:lang="en">Choudhury C, et al. The arylamine N-acetyltransferases as therapeutic targets in metabolic diseases associated with mitochondrial dysfunction. Pharmacological Reviews. 2024; 76(2): 300-320. doi: 10.1124/pharmrev.123.000835</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Salazar-González RA, Turiján-Espinoza E, Hein DW, Milán-Segovia RC, Uresti-Rivera EE, Portales-Pérez DP. Expression and genotype-dependent catalytic activity of N-acetyltransferase 2 (NAT2) in human peripheral blood mononuclear cells and its modulation by Sirtuin 1. Biochem Pharmacol. 2018; 156: 340-347. doi: 10.1016/j.bcp.2018.08.034</mixed-citation><mixed-citation xml:lang="en">Salazar-González RA, Turiján-Espinoza E, Hein DW, Milán-Segovia RC, Uresti-Rivera EE, Portales-Pérez DP. Expression and genotype-dependent catalytic activity of N-acetyltransferase 2 (NAT2) in human peripheral blood mononuclear cells and its modulation by Sirtuin 1. Biochem Pharmacol. 2018; 156: 340-347. doi: 10.1016/j.bcp.2018.08.034</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Никишина М.В., Вавилин В.А., Макарова С.И., Ляхович В.В. Анализ ассоциаций полиморфизмов гена NAT2 с риском возникновения рака легкого. Бюллетень экспериментальной биологии и медицины. 2007; 143(1): 89-92.</mixed-citation><mixed-citation xml:lang="en">Nikishina MV, Vavilin VA, Makarova SI, Lyakhovich VV. Analysis of associations of polymorphisms of the NAT2 gene with the risk of lung cancer. Bulletin of Experimental Biology and Medicine. 2007; 143(1): 89-92. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Silva IMD, Vacario BGL, Okuyama NCM, Barcelos GRM, Fuganti PE, Guembarovski RL, et al. Polymorphisms in drug-metabolizing genes and urinary bladder cancer susceptibility and prognosis: Possible impacts and future management. Gene. 2024; 907: 148252. doi: 10.1016/j.gene.2024.148252</mixed-citation><mixed-citation xml:lang="en">Silva IMD, Vacario BGL, Okuyama NCM, Barcelos GRM, Fuganti PE, Guembarovski RL, et al. Polymorphisms in drug-metabolizing genes and urinary bladder cancer susceptibility and prognosis: Possible impacts and future management. Gene. 2024; 907: 148252. doi: 10.1016/j.gene.2024.148252</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Elsalem L, Al Shatnawi A, A Alfaqih M, Alshoh A, Al Demour S, Al-Daghmin A, Halalsheh O, et al. Discovery of a novel genetic variant in the N-acetyltransferase2 (NAT2) gene that is associated with bladder cancer risk. Acta Biochim Pol. 2023; 70(3): 575-582. doi: 10.18388/abp.2020_6590</mixed-citation><mixed-citation xml:lang="en">Elsalem L, Al Shatnawi A, A Alfaqih M, Alshoh A, Al Demour S, Al-Daghmin A, Halalsheh O, et al. Discovery of a novel genetic variant in the N-acetyltransferase2 (NAT2) gene that is associated with bladder cancer risk. Acta Biochim Pol. 2023; 70(3): 575-582. doi: 10.18388/abp.2020_6590</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Camporez JP, Wang Y, Faarkrog K, Chukijrungroat N, Petersen KF, Shulman GI. Mechanism by which arylamine N-acetyltransferase 1 ablation causes insulin resistance in mice. Proc Natl Acad Sci U S A. 2017; 114(52): E11285-E11292. doi: 10.1073/pnas.1716990115</mixed-citation><mixed-citation xml:lang="en">Camporez JP, Wang Y, Faarkrog K, Chukijrungroat N, Petersen KF, Shulman GI. Mechanism by which arylamine N-acetyltransferase 1 ablation causes insulin resistance in mice. Proc Natl Acad Sci U S A. 2017; 114(52): E11285-E11292. doi: 10.1073/pnas.1716990115</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Walls KM. Heterocyclic amines and arylamine N-acetyltransferase 2 polymorphism in pathogenesis of insulin resistance. – 2021.</mixed-citation><mixed-citation xml:lang="en">Walls KM. Heterocyclic amines and arylamine N-acetyltransferase 2 polymorphism in pathogenesis of insulin resistance. – 2021.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Самгина Т.А. Влияние некоторых факторов риска и полиморфизма rs1799930 гена NAT2-590 G&gt;A на развитие хронического панкреатита. Научные результаты биомедицинских исследований. 2021; 7(2): 143-148. doi: 10.18413/2658-6533-2021-7-2-0-4</mixed-citation><mixed-citation xml:lang="en">Samgina TA. The influence of certain risk factors and polymorphism rs1799930 of the NAT2-590 G&gt;A gene on the development of chronic pancreatitis. Scientific results of biomedical research. 2021; 7(2): 143-148. (In Russ.). doi: 10.18413/2658-6533-2021-7-2-0-4</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Schnuch A, Westphal GA, Müller MM, Schulz TG, Geier J, Brasch J, et al. Genotype and phenotype of N-acetyltransferase 2 (NAT2) polymorphism in patients with contact allergy. Contact Dermatitis. 1998; 38(4): 20911. doi: 10.1111/j.1600-0536.1998.tb05709.x</mixed-citation><mixed-citation xml:lang="en">Schnuch A, Westphal GA, Müller MM, Schulz TG, Geier J, Brasch J, et al. Genotype and phenotype of N-acetyltransferase 2 (NAT2) polymorphism in patients with contact allergy. Contact Dermatitis. 1998; 38(4): 20911. doi: 10.1111/j.1600-0536.1998.tb05709.x</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Santos EC, Pinto AC, Klumb EM, Macedo JM. Polymorphisms in NAT2 (N-acetyltransferase 2) gene in patients with systemic lupus erythematosus. Rev Bras Reumatol Engl Ed. 2016; 56(6): 521-529. doi: 10.1016/j.rbre.2016.09.015</mixed-citation><mixed-citation xml:lang="en">Santos EC, Pinto AC, Klumb EM, Macedo JM. Polymorphisms in NAT2 (N-acetyltransferase 2) gene in patients with systemic lupus erythematosus. Rev Bras Reumatol Engl Ed. 2016; 56(6): 521-529. doi: 10.1016/j.rbre.2016.09.015</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Petryszyn P, Zurakowski G, Dudkowiak R, Machowska M, Gruca A, Ekk-Cierniakowski P, et al. The N-Acetyltransferase 2 Polymorphism and Susceptibility to Inflammatory Bowel Disease: A Case-Control Study. Pharmacol Res Perspect. 2025; 13(1): e70040. doi: 10.1002/prp2.70040</mixed-citation><mixed-citation xml:lang="en">Petryszyn P, Zurakowski G, Dudkowiak R, Machowska M, Gruca A, Ekk-Cierniakowski P, et al. The N-Acetyltransferase 2 Polymorphism and Susceptibility to Inflammatory Bowel Disease: A Case-Control Study. Pharmacol Res Perspect. 2025; 13(1): e70040. doi: 10.1002/prp2.70040</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Amorim G, Jaworski J, Yang J, Cordeiro-Santos M, Kritski AL, Figueiredo MC, et al. Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohort. Pharmacogenet Genomics. 2025; 35(2): 5564. doi: 10.1097/FPC.0000000000000552</mixed-citation><mixed-citation xml:lang="en">Amorim G, Jaworski J, Yang J, Cordeiro-Santos M, Kritski AL, Figueiredo MC, et al. Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohort. Pharmacogenet Genomics. 2025; 35(2): 5564. doi: 10.1097/FPC.0000000000000552</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">van Amerongen CCA, Kramer D, Pas HH, Schuttelaar MLA. The expression pattern of N-acetyltransferase 1 in healthy human skin. Contact Dermatitis. 2021; 85(1): 1-6. doi: 10.1111/cod.13821</mixed-citation><mixed-citation xml:lang="en">van Amerongen CCA, Kramer D, Pas HH, Schuttelaar MLA. The expression pattern of N-acetyltransferase 1 in healthy human skin. Contact Dermatitis. 2021; 85(1): 1-6. doi: 10.1111/cod.13821</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Salazar-González RA, Turiján-Espinoza E, Hein DW, Milán-Segovia RC, Uresti-Rivera EE, Portales-Pérez DP. Expression and genotype-dependent catalytic activity of N-acetyltransferase 2 (NAT2) in human peripheral blood mononuclear cells and its modulation by Sirtuin 1. Biochem Pharmacol. 2018; 156: 340-347. doi: 10.1016/j.bcp.2018.08.034</mixed-citation><mixed-citation xml:lang="en">Salazar-González RA, Turiján-Espinoza E, Hein DW, Milán-Segovia RC, Uresti-Rivera EE, Portales-Pérez DP. Expression and genotype-dependent catalytic activity of N-acetyltransferase 2 (NAT2) in human peripheral blood mononuclear cells and its modulation by Sirtuin 1. Biochem Pharmacol. 2018; 156: 340-347. doi: 10.1016/j.bcp.2018.08.034</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Hernández-González O, Martínez-Leija ME, Paz-Rodríguez VA, Portales-Pérez DP. Arylamines N-acetyltransferases 1 and 2: physiology, genetics and epigenetics. Gac Med Mex. 2024; 160(5): 473-479. doi: 10.24875/GMM.M24000946</mixed-citation><mixed-citation xml:lang="en">Hernández-González O, Martínez-Leija ME, Paz-Rodríguez VA, Portales-Pérez DP. Arylamines N-acetyltransferases 1 and 2: physiology, genetics and epigenetics. Gac Med Mex. 2024; 160(5): 473-479. doi: 10.24875/GMM.M24000946</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kresyun VJ, Меhlnychenko MG, Antonenko PB, Аntonenko KO, Кvashnina AA. Adhesion ileus in children in the connective tissues dysplasia. Klin Khir. 2016; (10): 21-5.</mixed-citation><mixed-citation xml:lang="en">Kresyun VJ, Меhlnychenko MG, Antonenko PB, Аntonenko KO, Кvashnina AA. Adhesion ileus in children in the connective tissues dysplasia. Klin Khir. 2016; (10): 21-5.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Nakai T, Sakai D, Nakamura Y, Horikita N, Matsushita E, Naiki M, et al. Association of NAT2 genetic polymorphism with the efficacy of Neurotropin® for the enhancement of aggrecan gene expression in nucleus pulposus cells: a pilot study. BMC Med Genomics. 2021; 14(1): 79. doi: 10.1186/s12920-021-00926-x</mixed-citation><mixed-citation xml:lang="en">Nakai T, Sakai D, Nakamura Y, Horikita N, Matsushita E, Naiki M, et al. Association of NAT2 genetic polymorphism with the efficacy of Neurotropin® for the enhancement of aggrecan gene expression in nucleus pulposus cells: a pilot study. BMC Med Genomics. 2021; 14(1): 79. doi: 10.1186/s12920-021-00926-x</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Родионова Л.В., Сороковиков В.А., Кошкарева З.В. Активность ферментных систем и метаболизм соединительной ткани в патогенезе стенозирующего процесса позвоночного канала (обзор литературы). Acta Biomedica Scientifica. 2015; 1: 77-83. .</mixed-citation><mixed-citation xml:lang="en">Rodionova LV, Sorokovikov VA, Koschkareva ZV. Enzyme systems activity and connective tissue metabolism as pathogenetic factors of spinal stenosis (literature review). Acta Biomedica Scientifica. 2015; 1: 77-83. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Lopes MQP, Teixeira RLF, Cabello PH, Nery JAC, Sales AM, Nahn JREP, et al. Human N-acetyltransferase 2 (NAT2) gene variability in Brazilian populations from different geographical areas. Front Pharmacol. 2023; 14: 1278720. doi: 10.3389/fphar.2023.1278720</mixed-citation><mixed-citation xml:lang="en">Lopes MQP, Teixeira RLF, Cabello PH, Nery JAC, Sales AM, Nahn JREP, et al. Human N-acetyltransferase 2 (NAT2) gene variability in Brazilian populations from different geographical areas. Front Pharmacol. 2023; 14: 1278720. doi: 10.3389/fphar.2023.1278720</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Ahmad MM, Amir N, Dhanasekaran S, John A, Abdulrazzaq YM, Ali BR, et al. Studies on N-Acetyltransferase (NAT2) Genotype Relationships in Emiratis: Confirmation of the Existence of Phenotype Variation among Slow Acetylators. Ann Hum Genet. 2017; 81(5): 190-196. doi: 10.1111/ahg.12198</mixed-citation><mixed-citation xml:lang="en">Al-Ahmad MM, Amir N, Dhanasekaran S, John A, Abdulrazzaq YM, Ali BR, et al. Studies on N-Acetyltransferase (NAT2) Genotype Relationships in Emiratis: Confirmation of the Existence of Phenotype Variation among Slow Acetylators. Ann Hum Genet. 2017; 81(5): 190-196. doi: 10.1111/ahg.12198</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Буловская Л.Н., Борисенко Г.Н., Дробаченко О.А. и др. Определение фенотипа N-ацетилтрансферазной активности. Лабораторное дело. 1990; 10: 28-30.</mixed-citation><mixed-citation xml:lang="en">Bulovskaya LN, Borisenko GN, Drobachenko OA, et al. Determination of the phenotype of N-acetyltransferase activity. Laboratory work. 1990; 10: 28-30. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Chen X, Guo Q, Li J, et al. The association between urinary caffeine and caffeine metabolites and diabetic retinopathy in individuals with diabetes: NHANES 2009–2014. Sci Rep. 2025; 15: 15827. doi: 10.1038/s41598-025-01088-x</mixed-citation><mixed-citation xml:lang="en">Chen X, Guo Q, Li J, et al. The association between urinary caffeine and caffeine metabolites and diabetic retinopathy in individuals with diabetes: NHANES 2009–2014. Sci Rep. 2025; 15: 15827. doi: 10.1038/s41598-025-01088-x</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Hill GM, Moriarity DM, Setzer WN. Attenuation of cytotoxic natural product DNA intercalating agents by caffeine. Sci Pharm. 2011; 79(4): 729-47. doi: 10.3797/scipharm.1107-19</mixed-citation><mixed-citation xml:lang="en">Hill GM, Moriarity DM, Setzer WN. Attenuation of cytotoxic natural product DNA intercalating agents by caffeine. Sci Pharm. 2011; 79(4): 729-47. doi: 10.3797/scipharm.1107-19</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Палковский О.Л., Михайлова Е.И., Кудря А.А., Шестопалов М.Ю. Клиренс мочевой кислоты как фармакогенетический маркер в определении фенотипа N-ацетилирования. Мат.конф. «Вопросы организации и информатизации здравоохранения». 2015: 79–83.</mixed-citation><mixed-citation xml:lang="en">Palkovsky OL, Mikhailova EI, Kudrya AA, Shestopalov MY. Uric acid clearance as a pharmacogenetic marker in determining the phenotype of N-acetylation. Mat.conf. “Issues of organization and informatization of healthcare”. 2015; 79-83. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Chavez Valdez R, Ahlawat R, Wills-Karp M, Nathan A, Ezell T, Gauda EB. Correlation between serum caffeine levels and changes in cytokine profile in a cohort of preterm infants. J Pediatr. 2011; 158(1): 57-64. doi: 10.1016/j.jpeds.2010.06.051</mixed-citation><mixed-citation xml:lang="en">Chavez Valdez R, Ahlawat R, Wills-Karp M, Nathan A, Ezell T, Gauda EB. Correlation between serum caffeine levels and changes in cytokine profile in a cohort of preterm infants. J Pediatr. 2011; 158(1): 57-64. doi: 10.1016/j.jpeds.2010.06.051</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Fujii R, Nakatochi M, Del Greco MF. Coffee Intake, Plasma Caffeine Levels, and Kidney Function: Two-Sample Mendelian Randomization among East Asian and European Ancestries. Kidney Int Rep. 2024; 9(4): 1083-1092. doi: 10.1016/j.ekir.2024.01.024</mixed-citation><mixed-citation xml:lang="en">Fujii R, Nakatochi M, Del Greco MF. Coffee Intake, Plasma Caffeine Levels, and Kidney Function: Two-Sample Mendelian Randomization among East Asian and European Ancestries. Kidney Int Rep. 2024; 9(4): 1083-1092. doi: 10.1016/j.ekir.2024.01.024</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Chen S, Zhang H, Su Q, Lin X, Kang K, Zhou Z, et al. Caffeine Intake Attenuates the Association of Cadmium Exposure with Cardiovascular Disease: National Health and Nutrition Examination Survey (NHANES) 2003-2016. Cardiovasc Toxicol. 2025; 25(10): 1506-1522. doi: 10.1007/s12012-025-10031-5</mixed-citation><mixed-citation xml:lang="en">Chen S, Zhang H, Su Q, Lin X, Kang K, Zhou Z, et al. Caffeine Intake Attenuates the Association of Cadmium Exposure with Cardiovascular Disease: National Health and Nutrition Examination Survey (NHANES) 2003-2016. Cardiovasc Toxicol. 2025; 25(10): 1506-1522. doi: 10.1007/s12012-025-10031-5</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Jaeschke H, Ramachandran A. Oxidant Stress and Lipid Peroxidation in Acetaminophen Hepatotoxicity. React Oxyg Species (Apex). 2018; 5(15): 145-158.</mixed-citation><mixed-citation xml:lang="en">Jaeschke H, Ramachandran A. Oxidant Stress and Lipid Peroxidation in Acetaminophen Hepatotoxicity. React Oxyg Species (Apex). 2018; 5(15): 145-158.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Wu D, Chen R, Zhang W, Lai X, Sun L, Li Q, et al. Tea and its components reduce the production of uric acid by inhibiting xanthine oxidase. Food Nutr Res. 2022; 66. doi: 10.29219/fnr.v66.8239</mixed-citation><mixed-citation xml:lang="en">Wu D, Chen R, Zhang W, Lai X, Sun L, Li Q, et al. Tea and its components reduce the production of uric acid by inhibiting xanthine oxidase. Food Nutr Res. 2022; 66. doi: 10.29219/fnr.v66.8239</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
